Currently, the U.S. Food and Drug Administration (FDA) and/or the European Medicines Agency (EMA) have approved two PD-1 antibodies (nivolumab and pembrolizumab) and two PD-L1 antibodies (atezolizumab and durvalumab) for the treatment of NSCLC [180–182]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.